All Oncology News

Talazoparib Plus Enzalutamide Improves OS in mCRPC

Daniel J. Campbell, TBE, CHFM, FASHE, received the Crystal Eagle Leadership Award from the American Society for Healthcare Engineering.

IMA203 Displays Efficacy in Heavily Pretreated Melanoma

The combination of talazoparib and enzalutamide improved overall survival in metastatic castration-resistant prostate cancer.

Kyle Doherty

Molecularly Targeted Therapeutics Are Precisely Aimed

IMA203, a TCR-T agent targeting PRAME, was safe and effective in patients with heavily pretreated melanoma.

Maurie Markman, MD

Sotigalimab May Be a Safe and Feasible Addition to the Rectal Cancer Chemoradiotherapy Paradigm

Maurie Markman, MD, details how the precision-medicine paradigm is a highly rational platform for antineoplastic drug development.

Todd Aguilera, MD, PhD, assistant professor, radiation oncology, UT Southwestern Medical Center

Ariana Pelosci

Tailored Approaches to TKI Dosing Allow for Treatment-Free Remissions and Reduced Toxicity in CML

Neoadjuvant sotigalimab plus chemoradiotherapy is safe and feasible compared with chemoradiotherapy alone in patients with rectal cancer.

Courtney Flaherty

2023 Chemotherapy Shortages Drove Altered Treatment Plans, Persistent Cost Increases

Elias Jabbour, MD, discusses how advancements in the administration and sequencing of TKIs have improved long-term prognosis for patients with CML.

Myelofibrosis Treatment Advances Rely on Past Developments to Drive Future Innovation

The 2023 cisplatin shortage led to shifts toward the use of alternative agents for use in head and neck cancer, as well as increased drug costs.

Study Finds Doctors and Patients Interested in Environmental Impact of Health Care Decisions

Idoroenyi Amanam, MD, discusses JAK inhibitor–associated AE management and considerations for the future use of stem cell transplant in myelofibrosis.

Dana-Farber Cancer Institute

Exploring Facets of Both the SCLC and NSCLC Therapeutic Landscapes

In focus groups conducted in the US, doctors and patients expressed openness to considering environmental factors when discussing treatment options.

Eric Kumar Singhi, MD, of MD Anderson Cancer Center

Ryan Scott

OncLive and the Ruesch Center for the Cure of Gastrointestinal Cancers Announce Recipients of the 2024 Luminary Awards in GI Cancers

Eric Kumar Singhi, MD, discusses the current therapeutic landscape and unmet needs in small cell and non–small cell lung cancer.

John L. Marshall, MD, director, Ruesch Center

OncLive

FDA Grants Orphan Drug Designation to Namodenoson for Pancreatic Cancer

OncLive and the Ruesch Center for the Cure of GI Cancers announce the winners of the 2024 Luminary Awards in GI Cancers.

LBL-024 Receives Breakthrough Therapy Designation in China for Extrapulmonary Neuroendocrine Carcinoma

The FDA has granted orphan drug designation to namodenoson for the treatment of patients with pancreatic cancer.

LBL-024 for Extrapulmonary Neuroendocrine Carcinoma | Image Credit: © catalin - stock.adobe.com

ODAC Weighs In on the Future of Perioperative Trial Designs in Resectable NSCLC

LBL-024 received breakthrough therapy designation in China for pretreated advanced extrapulmonary neuroendocrine carcinoma.

Megan Hollasch

PFS Data for 177Lu-Dotatate Surpass Clinical Benchmarks in Refractory Meningioma

John V. Heymach, MD, PhD, and Marina Chiara Garassino, MD, detail the 11-0 ODAC vote that new trial designs for perioperative regimens in resectable NSCLC should include within-trial assessment of each treatment phase's contribution.

Ariana Pelosci

Apalutamide Demonstrates Real-World OS Benefit vs Enzalutamide in mCSPC

Patients with WHO grade II/III recurrent meningioma experienced clinically meaningful efficacy with 177Lutetium-Dotatate.

Neal Shore, MD, FACS, steering committee chair, medical director, Carolina Urologic Research Center

Response-Based Intermittent Ibrutinib Dosing Shows Safety, Feasibility in CLL

Apalutamide was associated with an improved 24-month overall survival rate vs enzalutamide in metastatic castration-sensitive prostate cancer.

Jeanette Lundin, MD, PhD, Karolinska University Hospital

Jax DiEugenio

Nivolumab Plus Radiotherapy Reduces Rates of Biochemical Recurrence in Gleason Grade 5 Prostate Cancer

A phase 2 study of intermittent ibrutinib dosing shows reducing cardiovascular toxicity while maintaining efficacy in CLL.

Russ Conroy

JAK Inhibitors Diversify the Field of Myelofibrosis Symptom and Spleen Management

The combination of nivolumab plus radiotherapy reduces rates of biochemical recurrence in gleason grade 5 prostate cancer.

Fox Chase Cancer Center Welcomes Dr Alexander R. Vartanov

Idoroenyi Amanam, MD, discusses characteristics that make patients with myelofibrosis most likely to derive benefit from certain JAK inhibitors.

Fox Chase Cancer Center

Phase 3 Study of TAR-200/Cetrelimab Is Discontinued in MIBC

Fox Chase Cancer Center hired Alexander R. Vartanov, MD, as an assistant professor in the Department of Bone Marrow Transplant and Cellular Therapies.

urothelial cancer | Image Credit: © freshidea - stock.adobe.com

Perioperative Pembrolizumab Meets EFS End Point in Newly Diagnosed, Resected Stage III/IVA HNSCC

The SunRISe-2 trial of TAR-200 plus cetrelimab in muscle-invasive bladder cancer not undergoing radical cystectomy is being discontinued.

Marjorie Green, MD, senior vice president, head of oncology, global clinical development, Merck Research Laboratories

Caroline Seymour

PARP1-Selective Inhibitors Generate Excitement in Solid Tumors

Perioperative treatment with pembrolizumab and adjuvant radiotherapy improved EFS vs adjuvant radiotherapy in locally advanced head and neck squamous cell carcinoma.

Kyle Doherty

D-VRd Propels Toward SOC Status in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma

Neeraj Agarwal, MD, FASCO; Andrew J. Armstrong, MD, MSc; and Timothy A. Yap, MBBS, PhD, FRCP, detail the latest research on PARP1-selective inhibitors in oncology.

Saad Z. Usmani, MD, MBA, FACP, FASCO, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center

Courtney Flaherty

ADC and CDK4/6 Inhibitor Decision-Making and Sequencing Questions Abound in Breast Cancer

Saad Z. Usmani, MD, MBA, FACP, FASCO, expands on data from the CEPHEUS trial of D-VRd in transplant-ineligible/-deferred, newly diagnosed multiple myeloma.

Yuan Yuan, MD, PhD, a professor of medicine, the director of Breast Oncology, and the medical director of the Breast Oncology Disease Research Group at Cedars-Sinai Medical Center in Los Angeles, California, as well as a health sciences clinical professor at the University of California, Los Angeles